Eloralintide
An experimental weekly amylin receptor agonist from Eli Lilly. A phase 2 trial showed up to about 20% weight loss at 48 weeks.
- Evidence
- Ongoing clinical research
- Half-life
- Days
- Sources
- 2 cited
Is eloralintide FDA-approved?
Investigational. Not FDA-approved.
Overview
Eloralintide targets the amylin receptor selectively. In a 48-week phase 2 trial in adults with obesity, average weight loss ranged from about 9% on the lowest dose to about 20% on the highest, versus under 1% on placebo.
How it works
It switches on amylin receptors in the brain, which increases fullness after meals and slows the stomach.
How long does eloralintide stay in the body?
Long enough for once-weekly shots in trials.
What it's studied for
- Obesity
- Combination with GLP-1 medicines
Reported side effects
- Nausea, fatigue and other stomach side effects, mostly mild to moderate
Related: Petrelintide, Pemvidutide, Maridebart Cafraglutide, Pramlintide.
Sources
The studies and prescribing labels this page is written from.
- Eloralintide for the treatment of obesity: a 48-week phase 2 trial. Lancet, 2025 PubMed
- Eloralintide: from discovery to clinical proof of concept. Mol Metab, 2025 PubMed
